Preclinical and clinical studies have suggested the involvement of the endocannabinoid system in schizophrenia pathobiology. In addition, in vitro studies have shown the molecular pathways and biological processes associated with cannabinoids' effects in some cell types, such as glial cell cultures. Thus, the effects of cannabinoid drugs on these cells may contribute to our knowledge about the pathobiology of schizophrenia. Specifically, oligodendrocytes are associated with white matter deficits in schizophrenia. The modulation of their function, survival, and differentiation can result in new approaches to treat schizophrenia's white matter-associated deficits. Here we have investigated the effects of cannabidiol (CBD) on a human oligodendrocyte culture (MO3.13). In another experiment, we pretreated the MO3.13 with MK801, an in vitro model of study schizophrenia proposed by our group, in terms of protein expression. Methods: MO3.13 oligodendrocytes were treated with CBD (1µM), or MK801 (50 µM) followed by CBD (1 µM). After 8 hours, proteins were extracted from these cells, digested, and processed in a state-of-theart LC-MS/MS system. Quantitative proteomics approaches were then employed in a label-free fashion. Differentially expressed proteins were analyzed using systems biology in silico tools. Results: Analyses identified that several proteins were up-or down-regulated in response to CBD treatment. These proteins were analyzed in terms of biological processes, pathways, and functions. CBD affected the expression of 136 proteins. Some proteins such as the transient receptor potential channel, microtubule-associated proteins, Rho GTPase activating proteins
, and the calcium channel, voltage-dependent T type alpha 1H subunit, among others possibly involved in myelination process, were increased by CBD. Additionally, the MK801-treatment decreased proteins of cytoskeleton, microtubule and RHO GTPases activate KTN1. MK801 also increased proteins involved in glycolysis and eukaryotic translation initiation and CBD attenuated these changes. Discussion: Studies have shown the effects of CBD on the treatment of schizophrenia; but the mechanisms involved in its antipsychotic properties are not fully understood. Herein, we observed that CBD modulated the expression of proteins that can be implicated in schizophrenia pathobiology. For instance, MAPs functions are related to cytoskeleton organization, differentiation, and migration of oligodendrocytes. Studies have shown a decrease of MAPs in schizophrenia patients; thus, increasing MAP2 and MAP4 by CBD may be an interesting mechanism to treat and prevent cytoskeleton impairments in oligodendrocytes and neurons in schizophrenia. Moreover, CBD increased the voltage gated channel that is involved in cannabinoid retrograde signaling and glutamate and GABAergic neurotransmission. CACNA1H modulates Ca2+ levels and the synaptic vesicle cycle. To note, we also found effects of CBD on pathways and biological processes involved with schizophrenia pathobiology, such as glucose metabolism, axon guidance, and inflammation mediated by cytokine signaling. In relation to MK801-treatement, we observed that affected proteins involved in glycolysis and CBD attenuated this change, like antipsychotics (as demonstrated in Cassoli et al., 2016) . Moreover, MK801-treatment affected the RHO GTPases family that has been implicated in schizophrenia, and CBD increased these proteins. In summary, these proteomic findings may provide an integrated picture of the role of endocannabinoid signaling in oligodendrocyte cells and possible implications for schizophrenia's pathobiology. biology. The attachment of GlcNAc to serine or threonine (S/T) residues transiently adorns thousands of nuclear, cytosolic, and mitochondrial proteins and modulates protein function and localization via dynamic cooperation with kinase and phosphatase enzymes. O-GlcNAc transferase (OGT) exists in complex with S/T phosphatase subunits PP1β and PP1γ and, along with the activity of O-GlcNAcase (OGA), facilitates rapid cycling between O-GlcNAcylation and phosphorylation states to serve as an "on/off switch" for substrate activation. Altered levels of OGT, OGA, and/or O-GlcNAc have been shown to influence many pathways pertinent to schizophrenia (SZ) pathophysiology. Notably, elevated O-GlcNAc and enhanced O-GlcNAcylation mediate glucose tolerance and insulin resistance which can lead to diabetes, an illness often found comorbid with SZ. Elevated O-GlcNAcylation can also produce mitochondrial abnormalities consistent with those identified in SZ. In an exploratory study of glycosylation enzyme transcript expression, our lab found OGT mRNA levels 253% higher in SZ than non-psychiatrically ill comparison (COMP) subjects (p < 0.0001). Based on this evidence, we hypothesized that OGT protein levels or the ratio of OGT:OGA enzymes are elevated in SZ brain. Methods: Expression of OGT and OGA were measured using western blots of superior temporal gyrus (STG; Brodmann Area 22) homogenates from sex-and age-matched pairs of SZ and COMP subjects (N = 17). Standard immunoblotting methods and commercially available antibodies were used to detect the targets of interest and protein levels were normalized to intralane valosin containing protein (VCP) expression; VCP expression has previously been found to be unchanged in SZ STG.
F199. O-GLCNAC DYSREGULATION IN
Results: In the current study, we found OGA protein levels reduced 18% in SZ (p < 0.01) and SZ subjects demonstrate a trend toward increased ratios of OGT:OGA (p = 0.05). OGT was not different between groups (p = 0.77). Discussion: Our current results partially support our original hypothesis that an altered ratio of OGT:OGA may contribute to abnormalities of O-GlcNAcylation and consequent cellular metabolic abnormalities in SZ. A trend toward increased OGT:OGA along with decreased expression of OGA would produce the same functional outcome as the originally predicted OGT increase: upregulation of protein O-GlcNAcylation. Given that the mRNA study used samples of dorsolateral prefrontal cortex (DLPFC) while our protein-level measures were from STG, it is not inconceivable that potential O-GlcNAc dysregulation could arise from upregulated OGT in one brain region, but downregulated OGA in another. To elaborate on these findings, we will investigate OGT and OGA expression in the DLPFC and will assess total O-GlcNAcylation in both brain regions to determine functional consequences of altered enzyme expression.
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Background: Cilia are microtubule-based organelles present on the surface of many eukaryotic cell types critical for tissue homeostasis and proper organ development. Ciliary dysfunction underlies a growing list of human diseases and disorders collectively called ciliopathies such as Bardet-Biedl syndrome (BBS), Joubert syndrome, Meckel-Gruber syndrome and primary ciliary dyskinesia. Many ciliary proteins are associated with neuronal function consistent with neuronal developmental delays, cognitive, learning, and memory deficits observed in several ciliopathies, suggesting that ciliary dysfunction may contribute to pathogenesis of neuronal diseases and that an understanding of how ciliary proteins function together as a system would provide much needed mechanistic insights into their molecular etiologies.
Methods:
We constructed protein-protein interaction (PPI) networks of genes associated with cilia and those associated with 7 neuropsychiatric diseases: schizophrenia, attention deficit hyperactivity disorder, major
